Department of Pediatric Nephrology, Hepatology and Metabolic Diseases, Hannover Medical School, Hannover, Germany.
Curr Opin Organ Transplant. 2012 Oct;17(5):515-9. doi: 10.1097/MOT.0b013e328356b080.
The use of everolimus has recently emerged for solid-organ transplantation in children. This review gives an overview of the relevant studies and clinical trials involving the immunosuppressive effects of everolimus in child organ transplant.
The use of everolimus in pediatric organ transplantation is associated with a decrease in calcineurin inhibitor-related toxicity, better renal function, a low number of acute rejections, and an acceptable side-effect profile. Particularly, the use of everolimus reduces the incidence of virus infection and the risk of posttransplant lymphoproliferative disease.
Everolimus is an effective agent with several advantages for pediatric solid-organ transplantation. Future prospective, randomized controlled trials will have to be performed in order to validate the findings of these pilot trials.
依维莫司最近已应用于儿童实体器官移植。本文综述了涉及依维莫司在儿童器官移植中免疫抑制作用的相关研究和临床试验。
在儿科器官移植中使用依维莫司与钙调磷酸酶抑制剂相关毒性降低、肾功能改善、急性排斥反应发生率低和可接受的副作用谱相关。特别是，依维莫司的使用降低了病毒感染的发生率和移植后淋巴组织增生性疾病的风险。
依维莫司是一种有效的药物，在儿科实体器官移植中有多项优势。为了验证这些初步试验的结果，需要进行未来的前瞻性、随机对照试验。
